Alps Advisors Inc. grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 3.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 257,504 shares of the biotechnology company’s stock after purchasing an additional 8,360 shares during the quarter. Alps Advisors Inc. owned 0.09% of Exelixis worth $6,239,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of EXEL. Vanguard Group Inc. boosted its stake in shares of Exelixis by 7.2% in the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after purchasing an additional 1,706,893 shares during the period. Matrix Capital Management Company LP raised its holdings in Exelixis by 8.8% in the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after acquiring an additional 1,225,000 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Exelixis in the second quarter valued at approximately $28,689,000. Meditor Group Ltd raised its holdings in Exelixis by 5.5% in the second quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after acquiring an additional 1,046,000 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in Exelixis by 588.9% in the third quarter. First Trust Advisors LP now owns 1,086,135 shares of the biotechnology company’s stock valued at $26,317,000 after acquiring an additional 928,475 shares in the last quarter. 79.03% of the stock is owned by institutional investors and hedge funds.

Shares of Exelixis, Inc. (NASDAQ:EXEL) traded up $0.10 during trading on Friday, hitting $25.85. 2,050,200 shares of the stock were exchanged, compared to its average volume of 5,064,375. The firm has a market cap of $7,647.80, a PE ratio of 50.69, a price-to-earnings-growth ratio of 1.25 and a beta of 1.89. Exelixis, Inc. has a fifty-two week low of $14.22 and a fifty-two week high of $32.50.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.18. The business had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The company’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.04) EPS. sell-side analysts forecast that Exelixis, Inc. will post 0.45 earnings per share for the current fiscal year.

Several brokerages recently weighed in on EXEL. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a report on Wednesday, October 18th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Wednesday, October 18th. Needham & Company LLC raised their target price on shares of Exelixis from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, October 17th. Royal Bank Of Canada raised their target price on shares of Exelixis from $33.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, October 17th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 target price on shares of Exelixis in a report on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $31.38.

In related news, EVP Jeffrey Hessekiel sold 27,302 shares of Exelixis stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $24.28, for a total value of $662,892.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gisela Schwab sold 100,000 shares of Exelixis stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $23.79, for a total transaction of $2,379,000.00. The disclosure for this sale can be found here. Insiders sold a total of 970,152 shares of company stock worth $25,923,457 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alps Advisors Inc. Acquires 8,360 Shares of Exelixis, Inc. (EXEL)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/12/alps-advisors-inc-acquires-8360-shares-of-exelixis-inc-exel.html.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.